Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/8/2018 |
| Start Date: | May 8, 2018 |
| End Date: | January 1, 2020 |
| Contact: | Michelle Kim, M.D. |
| Email: | michekim@umich.edu |
| Phone: | 734-936-7810 |
A Prospective Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be
non-invasively identified using imaging phenotypes that identify regionally distinct areas of
tumor with genetic alterations that drive tumor resistance pathways. The researchers propose
a unique approach to assess initial GBM heterogeneity by performing histological and genomic
analysis of biopsies targeted by advanced MRI before treatment.
non-invasively identified using imaging phenotypes that identify regionally distinct areas of
tumor with genetic alterations that drive tumor resistance pathways. The researchers propose
a unique approach to assess initial GBM heterogeneity by performing histological and genomic
analysis of biopsies targeted by advanced MRI before treatment.
Inclusion Criteria:
- Suspected newly diagnosed or recurrent supratentorial glioblastoma eligible for
surgical biopsy and/or resection
- Patients must be 18 years of age or older
- Study-specific informed consent approved for this purpose by the IRB of the University
of Michigan
Exclusion Criteria:
- Patients unable to undergo MRI
We found this trial at
1
site
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
